The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis
- 26 July 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 167 (2) , 424-432
Abstract
Background Quantitative analysis of intravenous immunoglobulin (IVIg) treatment against toxic epidermal necrolysis (TEN) is lacking. Objectives To provide a meta‐analysis evidence‐based examination of IVIg efficacy against TEN. Methods A systematic review and meta‐analysis of literature published before 31 July 2011 was conducted. In observational controlled studies with at least eight patients with TEN receiving IVIg treatment, a pooled estimate of mortality risk was determined, comparing IVIg and supportive care. Statistical analyses were performed on raw data to compare the clinical differences between (i) high‐dose and low‐dose IVIg treatment in adult patients and (ii) paediatric and adult patients treated with IVIg. Results Seventeen studies met inclusion criteria. Overall mortality rate of patients with TEN treated with IVIg was 19·9%. The pooled odds ratio (OR) for mortality from six observational controlled studies comparing IVIg and supportive care was 1·00 [95% confidence interval (CI) 0·58–1·75; P = 0·99]. The pooled OR for mortality in patients treated with high‐dose IVIg vs. supportive care was 0·63 (95% CI 0·27–1·44; P = 0·27). Adults treated with high‐dose IVIg exhibited significantly lower mortality than those treated with low‐dose IVIg (18·9% vs. 50%, respectively; P = 0·022); however, multivariate logistic regression model adjustment indicated that IVIg dose does not correlate with mortality (high vs. low dose: OR 0·494; 95% CI 0·106–2·300; P = 0·369). Paediatric patients treated with IVIg had significantly lower mortality than adults (0% vs. 21·6%; P = 0·001). Conclusions Although high‐dose IVIg exhibited a trend towards improved mortality and children treated with IVIg had a good prognosis, the evidence does not support a clinical benefit of IVIg. Randomized controlled trials are necessary.Keywords
This publication has 20 references indexed in Scilit:
- Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR StudyJournal of the American Academy of Dermatology, 2008
- Toxic epidermal necrolysis (TEN) and Stevens–Johnson syndrome (SJS): Experience with high-dose intravenous immunoglobulins and topical conservative approachBurns, 2007
- Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: An open uncontrolled studyIndian Journal of Dermatology, Venereology and Leprology, 2005
- Treatment of Epidermal Necrolysis with High-Dose Intravenous Immunoglobulins (IVIg)Drugs, 2005
- High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefitsEye, 2004
- Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysisInternational Journal of Dermatology, 2004
- Toxic Epidermal Necrolysis: Does Immunoglobulin Make a Difference?Journal of Burn Care & Rehabilitation, 2004
- Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in childrenJournal of the American Academy of Dermatology, 2002
- Drug-Induced Stevens-Johnson Syndrome/Toxic Epidermal NecrolysisAmerican Journal of Clinical Dermatology, 2000
- Severe Adverse Cutaneous Reactions to DrugsNew England Journal of Medicine, 1994